Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
কীওয়ার্ডস
বিমূর্ত
বর্ণনা
Multiple myeloma is an incurable blood cancer of plasma cells that occurs in older individuals with a median age at diagnosis of 69 years and a median overall survival of 6-7 years [Kumar S.K., et al. Leukemia, 2014; Rollig C., et al. Lancet., 2015]. Over the past years novel agents have been introduced into clinical practice, showing improved overall response rates, progression-free survival and overall survival in patients with multiple myeloma. The main classes of novel agents include proteasome inhibitors, immunomodulatory agents and monoclonal antibodies. These agents are typically used in doublet or triplet regimens that include a chemotherapeutic drug and/or corticosteroid.
Streptococcus pneumoniae (pneumococcus) is a cause of worldwide morbidity and mortality. Patients with multiple myeloma are at high risk of developing life-threatening Streptococcus pneumoniae infections due to chemotherapy-associated immunosuppression. Vaccination is an important preventive strategy against infections caused by S. pneumoniae. In the past, the 23-valent pneumococcal polysaccharide vaccine was recommended. However, polysaccharide vaccines have limited efficacy in cancer and hematology patients, because of the decreased T- and B-cell responses. Clinical efficacy and safety of conjugate pneumococcal vaccines in multiple myeloma patients receiving novel agents have not been studied before.
In this study the investigators wish to study the effect of vaccination with 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel agents (proteasome inhibitors and immunomodulatory drugs). The main aim of this study is to assess the clinical efficacy and safety of 13-valent pneumococcal conjugate vaccine in multiple myeloma patients treated with novel agents.
তারিখ
| সর্বশেষ যাচাই করা হয়েছে: | 01/31/2020 |
| প্রথম জমা দেওয়া: | 07/16/2018 |
| আনুমানিক তালিকাভুক্তি জমা দেওয়া হয়েছে: | 08/04/2018 |
| প্রথম পোস্ট: | 08/06/2018 |
| সর্বশেষ আপডেট জমা দেওয়া হয়েছে: | 02/17/2020 |
| সর্বশেষ আপডেট পোস্ট: | 02/18/2020 |
| আসল অধ্যয়ন শুরুর তারিখ: | 06/30/2018 |
| আনুমানিক প্রাথমিক সমাপ্তির তারিখ: | 05/30/2020 |
| আনুমানিক অধ্যয়ন সমাপ্তির তারিখ: | 07/30/2020 |
অবস্থা বা রোগ
হস্তক্ষেপ / চিকিত্সা
Biological: Vaccination group
Drug: Standard prophylaxis
পর্যায়
বাহু গ্রুপ
| বাহু | হস্তক্ষেপ / চিকিত্সা |
|---|---|
| Experimental: Vaccination group Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later. | Biological: Vaccination group Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later. |
| Active Comparator: Standard prophylaxis Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents | Drug: Standard prophylaxis Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents. |
যোগ্যতার মানদণ্ড
| বয়স অধ্যয়নের জন্য যোগ্য | 18 Years প্রতি 18 Years |
| লিঙ্গ অধ্যয়নের জন্য যোগ্য | All |
| স্বাস্থ্যকর স্বেচ্ছাসেবীদের গ্রহণ করে | হ্যাঁ |
| নির্ণায়ক | Inclusion Criteria: - Patients with proven diagnosis of multiple myeloma - Patients must be enrolled in treatment with novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) - Patients must have Creatinine Clearance above 30 mL/min on the Day 1 of trial - Patients must have given informed consent to participate in trial. Exclusion Criteria: - Contraindication to the use of one of the study drug/vaccines (including known hypersensitivity) - Creatinine Clearance below 30 mL/min on the Day 1 of trial - Psychiatric disorder or unable to understand or to follow the protocol directions - Active bacterial, viral, fungal or protozoal infection on the Day 1 of trial |
ফলাফল
প্রাথমিক ফলাফল ব্যবস্থা
1. Incidence of clinically/radiologically confirmed pneumonia and episodes of febrile neutropenia during one year period after initiation of novel agents. [One year]
মাধ্যমিক ফলাফলের ব্যবস্থা
1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. [One year]
